Orthocell Secures U.S. Defence Network Approval for Remplir™
Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.
- Remplir™ approved for 51 DoD and 170 VA hospitals in the U.S.
- Orthocell leverages existing distributor network covering 17 states
- Device validated in 23 surgical procedures on injured soldiers in Ukraine
- Approval expands Orthocell’s access to key military and veteran healthcare markets
- Follows recent momentum in U.S. commercialization and revenue growth
Major U.S. Defence Channel Opens for Remplir™
Orthocell Limited (ASX:OCC) has secured a significant commercial milestone with approval for its Remplir™ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks. This green light unlocks access to 51 military hospitals and 170 VA medical centres, vastly expanding Orthocell’s footprint in a critical and specialised segment of the U.S. healthcare market.
The approval is particularly notable given the size and strategic importance of these networks, which serve complex trauma cases often encountered in military and veteran care. Orthocell’s existing U.S. distributor network, spanning 17 states, is well placed to target surgeons within these institutions, enabling efficient market penetration without the need for extensive new infrastructure.
Clinical Validation from Conflict Zones
Managing Director Paul Anderson emphasised the strategic value of this approval, stating it enables direct engagement with military and VA surgeons and leverages the company’s established distribution and medical education teams. This follows a period of accelerating commercial momentum in the U.S., as detailed in the company’s recent record half-year revenue report and expanding hospital accounts across 45 states. The current approval complements this trajectory, positioning Orthocell for further growth in specialised nerve repair markets.
Building on Growing U.S. Momentum
This development aligns with Orthocell’s broader U.S. strategy, which has seen the company rapidly increase its presence through regulatory clearances and distributor appointments. The company’s recent financial disclosures revealed a 48% jump in half-year revenue to $6.2 million, driven by Remplir™ sales and geographic expansion. Orthocell is also advancing regulatory submissions in Europe and Canada, aiming to capture a global nerve repair market estimated in the billions.
Orthocell’s approach to leveraging existing distributor relationships to access the DoD and VA networks reflects a pragmatic commercial strategy. This approval not only validates Remplir’s clinical credentials but also opens a pathway to a specialised and potentially lucrative segment of the U.S. healthcare system, where demand for effective nerve repair solutions is acute.
Bottom Line?
Orthocell’s DoD and VA approval marks a crucial step in commercialising Remplir™ within specialised U.S. military and veteran healthcare, setting the stage for deeper market penetration and revenue growth.
Questions in the middle?
- How quickly will Orthocell translate DoD and VA approvals into meaningful sales volumes?
- Will feedback from military surgeons in the U.S. and Ukraine influence further product development or marketing?
- Can Orthocell maintain momentum and secure additional approvals to cover all 50 U.S. states?
